Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8835488 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(8 years from now) | |
US9309234 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(8 years from now) | |
US11077098 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9642842 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 30, 2025 |
NCE-1 date: 2024-10-30
Market Authorisation Date: 30 October, 2020
Treatment: Management of acute pain by intravenous injection
Dosage: SOLUTION;INTRAVENOUS
11
United States
5
Japan
4
Israel
3
Korea, Republic of
3
European Union
2
Spain
2
Denmark
2
Poland
2
New Zealand
2
Portugal
2
Australia
2
Hungary
1
Hong Kong
1
RS
1
China
1
Brazil
1
Canada
1
EA
1
ME
1
Croatia
1
Cyprus
1
Lithuania
1
Slovenia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic